Emma Reeve
Independent DirectorMs. Emma Reeve, A.C.A. is Director at Myrobalan Therapeutics from October 2024. She serves as Board of Director of ReAlta Life Sciences, Inc. from July 9, 2024. She is Independent Board Director and Audit Chair of Cardurion Pharmaceuticals, Inc. from October 2023. She was Board Advisor of Myrobalan Therapeutics, Inc. until October 2024. She has global financial leadership and Board experience across pharmaceutical, medical device and biopharma companies. She serves as Independent Director at Ribon Therapeutics, Inc. Ms. Reeve serves as Independent Director at Whitehawk Therapeutics, Inc. (formerly known as Aadi Bioscience, Inc.) since September 8, 2021. Ms. Reeve served as Independent Director at Editas Medicine, Inc. since September 2021 until December 31, 2024 and served as its Chairman of the Board since June 2023 until December 31, 2024. Ms. Reeve had been Director of Ribon Therapeutics, Inc. since October 2020. Ms. Reeve had been the Chief Financial Officer at Constellation Pharmaceuticals, Inc. since October 24, 2017 until July 15, 2021 and served as its Treasurer and Secretary since December 2017 until September 2018 and served as its Senior Vice President. Ms. Reeve has been an Independent Director at PTC Therapeutics, Inc. since December 14, 2018. Ms. Reeve served as an Interim Chief Financial Officer at PAREXEL International Corporation since July 16, 2016 until May 15, 2017 and also its Corporate Vice President and Controller since September 2014 until May 15, 2017 where she was responsible for all aspects of financial reporting and accounting, Investor Relations, financial planning and analysis. Ms. Reeve served in various senior financial positions in the pharmaceutical industry, including Head of Finance and Administration for Novartis Pharma Switzerland from May 2012 to August 2014 and Vice President and Global Head Business Planning & Analysis for Novartis Vaccines and Diagnostics from January 2008 to April 2012. Prior to joining Novartis in 2008, she held several leadership financial positions, including serving as Chief Financial Officer for two biopharmaceutical companies. Ms. Reeve served as Chief Financial Officer of Inotek Pharmaceuticals Corporation since March 2006 to April 2008 and served as its Vice President since March 2006. In 1994, she joined Bristol-Myers Squibb (BMS), where she held various financial management positions at both the divisional and corporate level including her final position as Assistant Controller - Financial Analysis. Ms. Reeve also worked at Bristol-Myers Squibb Company, a biopharmaceutical company, from 1994 to 2002. While with Bristol-Myers Squibb, she held positions in Germany, Belgium and the United States. Prior to Bristol-Myers Squibb, Ms. Reeve held finance positions at Stryker Germany, Avon Cosmetics Germany and Michael Peters & Partners Limited and Spicer & Oppenheim in London. She served at Bristol Myers Squibb Company. Ms. Reeve was as Senior Director of Research Operations at Merck Research Laboratories from 2004 to 2006. In 2002, At Aton Pharma, Inc. she served as its Vice President and Chief Financial Officer from 2002 to 2004. Aside from her responsibilities in finance and operations at Aton, she also served as a lead Member of the team that sold it to Merck & Co. Inc. in March of 2004. Following the acquisition of Aton, she joined the Merck Research Laboratories? Boston team as site Head of Research Operations. Ms. Reeve is an associate of the Institute of Chartered Accountants in England & Wales. In this role, she and her team supported all aspects of the growth of the site from initial occupancy to the delivery of pre-clinical candidates in oncology. She is also a Member of the Board of Trustees of Tufts Medical Center. Ms. Reeve holds a B.Sc. in Computer Science from the University of London?s Imperial College and then qualified as a Chartered Accountant in the UK.
Positions
- Company NamePTC Therapeutics, Inc.Stock CodePTCTPositionIndependent DirectorColleagues
- MBMatthew B. KleinCEO & Director
- MSMichael SchmertzlerIndependent Chairman of the Board
- ASAllan Steven JacobsonCo-Founder & Independent Director
- PGPierre GravierChief Financial Officer
- NANeil AlmsteadChief Technical Operations Officer
- EPEric PauwelsChief Business Officer
- GDGlenn Daniel SteeleIndependent Director
